FR2454434A1 - Sels mixtes d'acides amines essentiels ou semi-essentiels et de produits analogues, exempts d'azote, de ces acides, et leur utilisation dans le traitement de desordres renaux et hepatiques - Google Patents

Sels mixtes d'acides amines essentiels ou semi-essentiels et de produits analogues, exempts d'azote, de ces acides, et leur utilisation dans le traitement de desordres renaux et hepatiques

Info

Publication number
FR2454434A1
FR2454434A1 FR8008318A FR8008318A FR2454434A1 FR 2454434 A1 FR2454434 A1 FR 2454434A1 FR 8008318 A FR8008318 A FR 8008318A FR 8008318 A FR8008318 A FR 8008318A FR 2454434 A1 FR2454434 A1 FR 2454434A1
Authority
FR
France
Prior art keywords
essential
semi
acids
amino acids
renal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8008318A
Other languages
English (en)
Other versions
FR2454434B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of FR2454434A1 publication Critical patent/FR2454434A1/fr
Application granted granted Critical
Publication of FR2454434B1 publication Critical patent/FR2454434B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A.COMPOSES UTILISABLES COMME MATIERE DE BASE D'ACIDES AMINES ESSENTIELS ET SEMI-ESSENTIELS DANS L'ORGANISME. B.CARACTERISES EN CE QU'ILS SONT CONSTITUES PAR LE PRODUIT REACTIONNEL D'UN ACIDE AMINE ESSENTIEL OU SEMI-ESSENTIEL AVEC L'ANALOGUE EXEMPT D'AZOTE D'UN ACIDE AMINE ESSENTIEL OU SEMI-ESSENTIEL, MAIS EXCLUANT LES PRODUITS REACTIONNELS DE L-ARGININE ET L-ORNITHINE AVEC DES ANALOGUES ALPHA-CETONIQUES A CHAINE RAMIFIEE D'ACIDES AMINES ESSENTIELS, CE PRODUIT REACTIONNEL ETANT FORME EN MILIEUX AQUEUX.
FR8008318A 1979-04-18 1980-04-14 Sels mixtes d'acides amines essentiels ou semi-essentiels et de produits analogues, exempts d'azote, de ces acides, et leur utilisation dans le traitement de desordres renaux et hepatiques Granted FR2454434A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/031,274 US4296127A (en) 1979-04-18 1979-04-18 Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof

Publications (2)

Publication Number Publication Date
FR2454434A1 true FR2454434A1 (fr) 1980-11-14
FR2454434B1 FR2454434B1 (fr) 1984-02-24

Family

ID=21858554

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8008318A Granted FR2454434A1 (fr) 1979-04-18 1980-04-14 Sels mixtes d'acides amines essentiels ou semi-essentiels et de produits analogues, exempts d'azote, de ces acides, et leur utilisation dans le traitement de desordres renaux et hepatiques

Country Status (16)

Country Link
US (1) US4296127A (fr)
JP (1) JPS6024094B2 (fr)
BE (1) BE882833A (fr)
CA (1) CA1139768A (fr)
DE (1) DE3015076A1 (fr)
DK (1) DK159147C (fr)
ES (1) ES490649A0 (fr)
FI (1) FI70206C (fr)
FR (1) FR2454434A1 (fr)
GB (1) GB2048867B (fr)
IE (1) IE49586B1 (fr)
IT (1) IT1141482B (fr)
LU (1) LU82369A1 (fr)
NL (1) NL191583C (fr)
NO (1) NO155239C (fr)
SE (1) SE460902B (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0179390A2 (fr) * 1984-10-19 1986-04-30 Institut Dr. Ziegler Pyruvate de L-lysine ou de L-histidine
EP0227545A2 (fr) * 1985-12-23 1987-07-01 The Johns Hopkins University Supplément nutritif pour le traitement de l'urémie
FR2615734A1 (fr) * 1987-05-27 1988-12-02 Synthelabo Compositions pharmaceutiques contenant un melange de sels de cetoacides et d'amino-acides utiles pour le traitement de l'uremie
US4908214A (en) * 1987-07-23 1990-03-13 Synthelabo Pharmaceutical tablet for the treatment of uraemia
EP0376215A2 (fr) * 1988-12-27 1990-07-04 Ajinomoto Co., Inc. Sels d'alpha-cétoacides avec aminoacides et leur procédé de préparation
EP0405295A2 (fr) * 1989-06-21 1991-01-02 Abbott Laboratories Formule alimentaire pour le traitement de maladies rénales

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0168425A4 (fr) * 1984-01-16 1989-03-09 Baxter Travenol Lab Nutrition par voie parenterale avec des triglycerides a chaine moyenne et longue.
US4677121A (en) * 1985-01-22 1987-06-30 The Johns Hopkins University Method of inhibiting muscle protein degradation
US4744990A (en) * 1986-09-25 1988-05-17 W. R. Grace & Co. Hydantoins as animal food supplements
US4871552A (en) * 1986-09-25 1989-10-03 W. R. Grace & Co.-Conn. Hydantoins as animal food supplements
DE3936319C3 (de) * 1989-11-01 1997-05-07 Bartz Volker Phosphatbinder zur oralen Verabreichung
DE3940052A1 (de) * 1989-12-04 1991-06-06 Nephro Medica Pharma Dialysier- und spuelloesung zur intraperitonealen verabreichung
DE3943424A1 (de) * 1989-12-30 1991-07-04 Nephro Medica Pharma Infusions- und injektionsloesung zur intravenoesen verabreichung
US5234696A (en) * 1991-12-27 1993-08-10 Abbott Laboratories Method of producing tablets, tablets produced thereby, and method of treatment using same
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
US5276018A (en) * 1992-07-17 1994-01-04 Brigham And Women's Hospital Composition comprising amino acids and methods for decreasing muscle breakdown
US20070141181A1 (en) 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6797289B2 (en) * 1998-02-13 2004-09-28 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
WO1999043336A1 (fr) 1998-02-27 1999-09-02 Nutramax Laboratories, Inc. L-ergothioneine, laiteron et s-adenosylmethionine servant a prevenir, a traiter et a reparer des dommages du foie
US20010000472A1 (en) * 1998-02-27 2001-04-26 Nutramax Laboratories, Inc. L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage
US8680329B2 (en) * 2010-10-13 2014-03-25 Tianjin Tiancheng Pharmaceutical Co., Ltd. (China) Process for preparation of α-ketoglutaric acid
US8754256B2 (en) * 2010-10-13 2014-06-17 Tianjin Tiancheng Pharmaceutical Co., Ltd. (China) Process for preparation of L-Arginine α-ketoglutarate 1:1 and 2:1
US20140187815A1 (en) * 2012-12-28 2014-07-03 Guoji Zhang Process for preparation of l-arginine alpha-ketoglutarate 1:1 and 2:1
US20220204918A1 (en) * 2019-04-11 2022-06-30 Merck Patent Gmbh Cell culture media comprising keto acids

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2226993A1 (en) * 1972-07-13 1974-11-22 Mackensie Walker Keto acid compsns. - for increasing protein synthesis and suppressing urea formation
FR2226994A1 (fr) * 1973-04-30 1974-11-22 Walser Mac Kenzie
FR2274290A2 (fr) * 1974-04-15 1976-01-09 Univ Johns Hopkins Medicament a base d'alpha-hydroxy-acides analogues d'amino-acides, en association avec des acides alpha-cetoniques analogues d'amino-acides, pour favoriser la synthese des proteines et supprimer la formation de l'uree dans l'organisme
FR2315916A2 (fr) * 1976-03-23 1977-01-28 Univ Johns Hopkins Melanges therapeutiques comprenant des analogues alpha hydroxy acides d'acides amines essentiels et leur administration a l'homme en vue de l'amelioration de la synthese proteique et la suppression de la formation d'uree
FR2419723A1 (fr) * 1978-03-17 1979-10-12 Univ Johns Hopkins Sels d'ornithine et d'arginine d'acides cetoniques a chaine ramifiee, et leur utilisation pour le traitement des affections hepatiques et renales

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2457820A (en) * 1945-12-27 1949-01-04 Merck & Co Inc Amino acid solution and process for preparing the same
US3441650A (en) * 1965-07-23 1969-04-29 Lab Jacques Logeais Sa Therapy of ammonical intoxications by di-l-ornithine alpha-ketoglutarate
US3764703A (en) * 1969-11-07 1973-10-09 Astra Ab Amino acid mixture for use in treatment of uremic conditions
US4100161A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
DE2759133A1 (de) * 1976-12-31 1978-07-13 Carmelo Prof Giordano Gemisch essentieller aminosaeuren und/oder analoger ketosaeuren und verwendung derselben diaetzusatz bei niereninsuffizienz

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2226993A1 (en) * 1972-07-13 1974-11-22 Mackensie Walker Keto acid compsns. - for increasing protein synthesis and suppressing urea formation
FR2226994A1 (fr) * 1973-04-30 1974-11-22 Walser Mac Kenzie
FR2274290A2 (fr) * 1974-04-15 1976-01-09 Univ Johns Hopkins Medicament a base d'alpha-hydroxy-acides analogues d'amino-acides, en association avec des acides alpha-cetoniques analogues d'amino-acides, pour favoriser la synthese des proteines et supprimer la formation de l'uree dans l'organisme
FR2315916A2 (fr) * 1976-03-23 1977-01-28 Univ Johns Hopkins Melanges therapeutiques comprenant des analogues alpha hydroxy acides d'acides amines essentiels et leur administration a l'homme en vue de l'amelioration de la synthese proteique et la suppression de la formation d'uree
FR2419723A1 (fr) * 1978-03-17 1979-10-12 Univ Johns Hopkins Sels d'ornithine et d'arginine d'acides cetoniques a chaine ramifiee, et leur utilisation pour le traitement des affections hepatiques et renales

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0179390A2 (fr) * 1984-10-19 1986-04-30 Institut Dr. Ziegler Pyruvate de L-lysine ou de L-histidine
EP0179390A3 (fr) * 1984-10-19 1987-07-29 Institut Dr. Ziegler Pyruvate de L-lysine ou de L-histidine
EP0227545A2 (fr) * 1985-12-23 1987-07-01 The Johns Hopkins University Supplément nutritif pour le traitement de l'urémie
EP0227545A3 (en) * 1985-12-23 1988-01-20 The John Hopkins University Nutritional supplement for treatment of uremia
FR2615734A1 (fr) * 1987-05-27 1988-12-02 Synthelabo Compositions pharmaceutiques contenant un melange de sels de cetoacides et d'amino-acides utiles pour le traitement de l'uremie
EP0295166A1 (fr) * 1987-05-27 1988-12-14 Synthelabo Compositions pharmaceutiques contenant un mélange de sels de cétoacides et d'amino-acides
US4908214A (en) * 1987-07-23 1990-03-13 Synthelabo Pharmaceutical tablet for the treatment of uraemia
EP0376215A2 (fr) * 1988-12-27 1990-07-04 Ajinomoto Co., Inc. Sels d'alpha-cétoacides avec aminoacides et leur procédé de préparation
EP0376215A3 (fr) * 1988-12-27 1991-03-27 Ajinomoto Co., Inc. Sels d'alpha-cétoacides avec aminoacides et leur procédé de préparation
EP0405295A2 (fr) * 1989-06-21 1991-01-02 Abbott Laboratories Formule alimentaire pour le traitement de maladies rénales
EP0405295A3 (en) * 1989-06-21 1991-03-27 Abbott Laboratories Improved nutritional formulation for the treatment of renal disease

Also Published As

Publication number Publication date
NL191583C (nl) 1995-10-03
IT1141482B (it) 1986-10-01
SE8002900L (sv) 1980-12-12
US4296127A (en) 1981-10-20
DK159147C (da) 1991-02-11
LU82369A1 (fr) 1980-07-31
NL191583B (nl) 1995-06-01
GB2048867B (en) 1983-03-16
FI801225A (fi) 1980-10-19
CA1139768A (fr) 1983-01-18
IT8021498A0 (it) 1980-04-18
DE3015076C2 (fr) 1988-01-21
JPS5653641A (en) 1981-05-13
NO155239C (no) 1987-03-04
DK163180A (da) 1980-10-19
ES8102804A1 (es) 1981-02-16
NO801119L (no) 1980-10-20
GB2048867A (en) 1980-12-17
ES490649A0 (es) 1981-02-16
IE800781L (en) 1980-10-19
FI70206B (fi) 1986-02-28
DE3015076A1 (de) 1980-10-30
BE882833A (fr) 1980-08-18
FR2454434B1 (fr) 1984-02-24
NL8002297A (nl) 1980-10-21
SE460902B (sv) 1989-12-04
NO155239B (no) 1986-11-24
FI70206C (fi) 1986-09-15
IE49586B1 (en) 1985-10-30
DK159147B (da) 1990-09-10
JPS6024094B2 (ja) 1985-06-11

Similar Documents

Publication Publication Date Title
FR2454434A1 (fr) Sels mixtes d'acides amines essentiels ou semi-essentiels et de produits analogues, exempts d'azote, de ces acides, et leur utilisation dans le traitement de desordres renaux et hepatiques
DE69020422D1 (de) Zusammensetzung in Form eines Schaumes enthaltend 5-Aminosalicylic Säure zur intra-rektal Verabreichung.
TR199901132T2 (xx) N-(aril/heteoaril) amino asit t�revleri, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler.
JPS55138393A (en) Semisynthesis of insulin
ATE13891T1 (de) Glutaminhaltige aminosaeure-zubereitungen.
NL155264B (nl) Werkwijze voor de bereiding van een in water onoplosbaar chelaat van een biologisch werkzaam aminozuur, zuuramide of aminoglycoside, alsmede een geheel of gedeeltelijk uit zo'n onoplosbaar chelaat bestaand gevormd voortbrengsel.
WO1992016205A3 (fr) Nouveaux derives de 2-carboxyindoles ayant une action pharmaceutique
YU30291A (sh) POSTUPAK ZA DOBIVANJE (2R,3R)-CIS-Гџ-FENILGLICIDNE KISELINE
PT86121A (en) Salt of diclofenac with a cyclic organic base and pharmaceutical compositions which contain it
PT90254A (pt) Processo para a preparacao de amidas de acidos ciclometileno -1,2-dicarboxilicos com actividade terapeutica e de composicoes farmaceuticas que as contem
NL7601132A (en) Cytotoxic medicaments bonded to polymeric carrier - e.g. dextran, which is itself bonded to immunoglobulin specific for cells to be killed
NO178325C (no) Fremgangsmåte for fremstilling av et t-PA injeksjonspreparat
GB1158727A (en) Amino Acid Derivatives
ES2084348T3 (es) N-((4,5-dihidroxi- y 4,5,8-trihidroxi-9,10-dihidro-9,10-dioxo-2-antracen-il)carbonil)aminoacidos utiles en la terapia de afecciones osteoarticulares.
Wickremasinghe et al. Site of biosynthesis and translocation of theanine in the tea plant
PT75949A (fr) Procede pour la preparation de derives d'acides amines en n-(vinblastinoil-23)
MX9204905A (es) Acidos aminometanodifosfonicos n-substituidos y procedimiento para su obtencion
IL59083A0 (en) Pharmaceutical composition containing thymidine
IL86638A0 (en) (2-cyano-2-oximinoacetyl)-amino acid derivatives,their preparation and their use as pesticides
FR2429015A2 (fr) Utilisation d'esters d'acides hydroxycarboxyliques aliphatiques en tant que desodorisants
IL86637A0 (en) (2-cyano-2-oximinoacetyl)-amino acid derivatives,their preparation and their use as pesticides
ATE149T1 (de) 2-(n-(2'-chlor-4'-methylthienyl-3')-n-(cyclopropyl- methyl)-amino)-imidazolin-(2), dessen saeureadditionssalze, dieses enthaltende arzneimittel und verfahren zu seiner herstellung.
FR2632643B1 (fr) Nouveau procede de preparation de derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique
DE3068886D1 (en) 7,8-dihydroxy-1-(sulfamylphenyl)-2,3,4,5-tetrahydro-1h-3-benzazepine derivatives, a process for their preparation and compositions containing them
ZA873965B (fr)

Legal Events

Date Code Title Description
ST Notification of lapse